Overview

This trial is active, not recruiting.

Condition anthrax
Treatment px563l, rpa563, or placebo
Phase phase 1
Sponsor Pfenex, Inc
Collaborator Department of Health and Human Services
Start date December 2015
End date June 2017
Trial size 54 participants
Trial identifier NCT02655549, PF563-101

Summary

The trial investigates Px563L and RPA563, two formulations of a novel anthrax vaccine.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety study
Intervention model parallel assignment
Masking double blind (subject, caregiver, investigator, outcomes assessor)
Primary purpose prevention
Arm
(Experimental)
Intramuscular injections of Px563L, RPA563, or placebo
px563l, rpa563, or placebo
Two intramuscular injections
(Experimental)
Intramuscular injections of Px563L, RPA563, or placebo
px563l, rpa563, or placebo
Two intramuscular injections
(Experimental)
Intramuscular injections of Px563L, RPA563, or placebo
px563l, rpa563, or placebo
Two intramuscular injections

Primary Outcomes

Measure
Adverse events (AE) and adverse events of special interest (AESI) for vaccines
time frame: 393 days

Secondary Outcomes

Measure
Anthrax toxin neutralizing antibody (TNA) 50% neutralization factor (NF50) value
time frame: 182 days

Eligibility Criteria

Male or female participants from 18 years up to 55 years old.

Inclusion Criteria: - Willing and able to read and understand the consent process and sign an informed consent form (ICF). - Females or males between the ages of 18 and 55, inclusive, at the time of informed consent. - Healthy or with stable medical conditions not requiring continuous medication. Exclusion Criteria: - Female subjects who are pregnant or breastfeeding. - A history of anthrax disease or receipt of an anthrax vaccine at any time in the past, exposure to or infection with B. anthracis, or has received any investigational anthrax vaccine or treatment (e.g., monoclonal antibodies, anthrax immune globulin). - Positive test for human immunodeficiency virus (HIV), hepatitis C or hepatitis B (surface antigen). - History of any malignant neoplasm or receipt of anti-neoplastic agents within the last 5 years, with the exception of adequately treated, localized or in situ non-melanoma of the skin (e.g., basal cell carcinoma) or of the cervix. - History of immunodeficiency, chronic illness requiring continuous or frequent medical intervention, autoimmune disease, bleeding disorder, hemoglobinopathy, prior solid organ or bone marrow transplant, or any known history in the past 5 years of cardiac disease. - Evidence of alcohol abuse (i.e., requiring treatment) or substance abuse (i.e., any use of illicit drugs) within 6 months prior to screening. - History of severe allergy (e.g., anaphylaxis) to latex or rubber. - Subjects who have significant scarring, tattoos, abrasions, rash, or other skin abnormality at the planned vaccination site that could interfere with evaluation of injection site.. - Use of any systemic steroids or other immunosuppressive agents within 2 years prior to screening; or use of topical, intranasal, or inhaled corticosteroids for ≥10 consecutive days within 1 year prior to screening. - Administration of any licensed vaccines within 30 days prior to screening. - History of anaphylaxis or other serious adverse reaction to vaccines. - Donation or loss of >500 mL of blood or donation of plasma within 2 months of screening, or recipient of blood or blood products within 2 months of screening. - Present or former member of US military or reservist who may have or will receive the licensed anthrax vaccine, or who has served in any military arena from January 1990 through present time. - May be at risk for exposure to anthrax or may be required to receive the licensed anthrax vaccine (e.g., postal workers). - Has previously participated in any anthrax vaccine or anti-protective antigen (PA) monoclonal antibody clinical trial.

Additional Information

Official title A Phase 1a Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation Study Assessing Safety and Immunogenicity of Px563L and RPA563 Administered by Intramuscular Injection in Healthy Adult Volunteers
Principal investigator Barbara K Lomeli, M.D.
Description This is a Phase 1, double-blind, randomized, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of Px563L or RPA563 administered intramuscularly. All subjects will be followed for safety and tolerability for 393 days after the initial vaccination. Immunogenicity analyses will be performed for up to 182 days, including an interim analysis based on Day 70 results, after the initial vaccination.
Trial information was received from ClinicalTrials.gov and was last updated in May 2016.
Information provided to ClinicalTrials.gov by Pfenex, Inc.